The Fred Hutchinson/University of Washington Cancer Consortium (Consortium), formed in 2002, is a partnership of: Fred Hutchinson Cancer Research Center, an NCI-designated Comprehensive Cancer Center since 1976 and a CCSG grant recipient since 1973;the University of Washington;and Children's Hospital and Regional Medical Center. The Consortium brings together more than 400 faculty with research interests in basic, clinical and public health sciences related to cancer, with total NCI funding of $73 million (direct costs). The goal of the Consortium is the elimination of cancer through more effective prevention, diagnostics, and treatment, deriving from fundamental insights into the biology of the disease. The extensive interdisciplinary collaboration between the three institutions in the cancer research disciplines of basic, clinical, and public health sciences affords new opportunities to reduce suffering and mortality from cancer. The Consortium faculty are organized into 13 productive research programs with emphasis in the Public Health (Biostatistics, Epidemiology, Cancer Prevention), Clinical (Transplantation Biology and Clinical Transplantation), and Fundamental sciences (Basic Sciences, Stem/Progenitor Cell Biology, Genome Instability &Mutagenesis), as well as programs that are highly cross-disciplinary (Women's Cancer;Prostate Cancer;Gl Cancer Etiology, Prevention, &Early Detection;Cancer Imaging;and Immunology &Vaccine Development). During the next grant period the Consortium will seek to: (1) Strengthen its clinical research programs and infrastructure to permit more rapid development of diagnostics and therapeutics;(2) Strengthen its presence in genetic/genomics;(3) Strengthen its presence in computational biology;(4) Continue its commitment to early cancer detection, including protein biomarker discovery and molecular diagnostics;(5) Build on leadership in research on infectious diseases and virology and develop a program focusing on infectious agents and cancer;(6) Continue to recruit promising laboratory scientists in broad areas of basic biology;and (7) Continue to encourage and support a focus on aging for relevant programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-39S6
Application #
8866503
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-01-01
Project End
2014-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
39
Fiscal Year
2014
Total Cost
$75,000
Indirect Cost
$32,386
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Montgomery, Elizabeth T; Noguchi, Lisa M; Dai, James Y et al. (2018) Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS Behav 22:402-411

Showing the most recent 10 out of 1267 publications